Summary
Pfizer Inc. (PFE) filed an 8-K on October 15, 2009, to provide an update on its pending acquisition of Wyeth. Key developments include the approval of the merger by Wyeth's stockholders, the completion of necessary financing by Pfizer, and the satisfaction of regulatory agency requirements. The merger agreement, initially dated January 25, 2009, and amended on September 30, 2009, outlines the merger of Wyeth into a wholly-owned subsidiary of Pfizer, with Wyeth surviving. This filing also includes unaudited pro forma condensed combined financial statements for Pfizer and Wyeth as of and for the six months ended June 28, 2009, and for the year ended December 31, 2008. Additionally, Wyeth's unaudited historical consolidated condensed financial statements for the six months ended June 30, 2009, are attached. Investors are encouraged to review these financial statements for a clearer understanding of the potential combined entity's financial position. The report also reiterates forward-looking statements and associated risks, urging investors to consult prior SEC filings for detailed risk factors.
Key Highlights
- 1Pfizer's acquisition of Wyeth is progressing, with Wyeth stockholders and regulatory agencies having approved the merger.
- 2Pfizer has successfully completed the financing required for the acquisition.
- 3The merger is subject to customary closing conditions.
- 4The filing includes unaudited pro forma combined financial statements for Pfizer and Wyeth as of and for recent periods.
- 5Wyeth's unaudited historical financial statements for the six months ended June 30, 2009, are provided.
- 6The report contains forward-looking statements and references prior filings for a comprehensive list of risks and uncertainties associated with the merger.
- 7Investors are directed to review additional filings and company websites for detailed information regarding the transaction and involved parties.